Melanotan II Injection for Erectile Dysfunction Evaluation:

Journal Context: Urology / ScienceDirect | Identifiers: DOI: 10.1016/S0090-4295(98)00282-5 / PMID: 9751121

Principal Investigators: Dorr, R. T., Hadley, M. E., Levine, S. B., et al. (University of Arizona College of Medicine, Tucson)

Methodology: A double-blind, placebo-controlled crossover human clinical study evaluating male subjects presenting with established psychogenic erectile dysfunction. Over separate testing intervals, participants received a subcutaneous injection of MT-2 at a baseline dose configuration of $0.025\text{ mg/kg}$ body weight to monitor spontaneous erectile events and calculate tip rigidity velocities via RigiScan verification engines.

Key Findings: Clinical tracking confirmed that MT-2 acted as a potent central stimulator of sexual arousal. In the absolute absence of visual or physical stimulation, $80\%$ of the treated subjects experienced fully apparent, functional erections. Rigidity tracking logged an average tip erection duration of 38 minutes on active MT-2 compared to just 3 minutes on placebo. The trial noted systemic side effects, including transient nausea, spontaneous yawning, and facial flushing, proving that MT-2 alters central neurochemical signaling pathways.